Skip to main content
Premium Trial:

Request an Annual Quote

Promega, ATCC Partner on Bioassays for Biologics Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Promega and ATCC today announced a collaboration for cell banking and bioproduction of cells in order to create bioluminescence-based drug discovery assays for biologics.

The deal calls for ATCC to produce and authenticate cell banks and production lots of engineered and stock cell lines for use as cellular reagents as Promega creates a line of new cell-based assay systems for biologics. The initial system will be for biologics drug discovery.

The first product offering from the partnership will be an antibody-dependent cell-mediated cytotoxicity reporter assay from Promega, to be launched sometime this year. This and other reporter assays to be developed will provide reduced variability to bioassays for biologics, Promega said in a statement.

The ADCC and other bioassay systems are currently in alpha and beta testing programs for qualification by biologic drug manufacturers.

Financial and other details of the deal were not disclosed.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.